Evaluation of the nonparametric estimation method in nonmem VI: application to real data
暂无分享,去创建一个
Mats O. Karlsson | Radojka M. Savic | Justin J. Wilkins | Paul G. Baverel | R. Savic | M. Karlsson | J. Wilkins | P. Baverel
[1] Mats O. Karlsson,et al. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial , 2003, European Journal of Clinical Pharmacology.
[2] D. B. White,et al. An evaluation of point and interval estimates in population pharmacokinetics using Nonmem analysis , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[3] Mats O. Karlsson,et al. Mechanism-based pharmacokinetic and pharmacodynamic modelling of tesaglitazar in type 2 diabetes patients , 2006 .
[4] Mats O Karlsson,et al. Application of population pharmacokinetics to cladribine , 2005, BMC pharmacology.
[5] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[6] M O Karlsson,et al. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone , 1998, Clinical pharmacology and therapeutics.
[7] A. Mallet. A maximum likelihood estimation method for random coefficient regression models , 1986 .
[8] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Alain Durand,et al. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[10] Grant Langdon,et al. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients , 2006, European Journal of Clinical Pharmacology.
[11] Mats O Karlsson,et al. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. , 2008, British journal of clinical pharmacology.
[12] R. Tibshirani,et al. Generalized Additive Models , 1991 .
[13] Mats O Karlsson,et al. Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.
[14] R. Tibshirani,et al. Generalized additive models for medical research , 1986, Statistical methods in medical research.
[15] L Aarons,et al. Population pharmacokinetics of tobramycin. , 1989, British journal of clinical pharmacology.
[16] M. Karlsson,et al. Population pharmacokinetic‐pharmacodynamic modeling of moxonidine using 24‐hour ambulatory blood pressure measurements , 1998, Clinical pharmacology and therapeutics.
[17] Michel Tod,et al. Evaluation of Uncertainty Parameters Estimated by Different Population PK Software and Methods , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[18] Djalil Chafaï,et al. Comparison of nonparametric methods in nonlinear mixed effects models , 2009, Comput. Stat. Data Anal..
[19] Mats O. Karlsson,et al. Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[20] M O Karlsson,et al. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. , 1997, British journal of clinical pharmacology.
[21] Robert Leary,et al. Parametric and Nonparametric Population Methods , 2006, Clinical pharmacokinetics.
[22] France Mentré,et al. Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine , 1988, Journal of Pharmacokinetics and Biopharmaceutics.
[23] Andrew C. Hooker,et al. Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method , 2007, Pharmaceutical Research.
[24] Lewis B. Sheiner,et al. Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[25] E. Niclas Jonsson,et al. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..
[26] Mats O. Karlsson,et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[27] M. O. Karlsson,et al. The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[28] R. Savic,et al. Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults , 2006, Journal of clinical pharmacology.
[29] A Schumitzky,et al. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. , 2000, Therapeutic drug monitoring.
[30] M O Karlsson,et al. Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. , 2001, British journal of clinical pharmacology.
[31] Mats O Karlsson,et al. Evaluation of the nonparametric estimation method in NONMEM VI. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[32] Manuel Hidalgo,et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. , 2006, Journal of the National Cancer Institute.
[33] Mats O. Karlsson,et al. Evaluation of an Extended Grid Method for Estimation Using Nonparametric Distributions , 2009, The AAPS Journal.
[34] Mats O. Karlsson,et al. Ximelagatran in extended secondary prevention of venous thromboembolism: Pharmacokinetics, pharmacodynamics and relationships to clinical events , 2006 .
[35] Mats O Karlsson,et al. Population pharmacokinetics of levosimendan in patients with congestive heart failure. , 2003, British journal of clinical pharmacology.
[36] Roger W. Jelliffe,et al. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) population models , 2001, Proceedings 14th IEEE Symposium on Computer-Based Medical Systems. CBMS 2001.